A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
Condition(s):Hepatocellular CarcinomaLast Updated:April 1, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Hepatocellular CarcinomaLast Updated:April 1, 2016Completed
Condition(s):Rheumatoid ArthritisLast Updated:February 10, 2014Terminated
Condition(s):Bone LesionLast Updated:February 28, 2024Completed
Condition(s):Acute Myelogenous Leukemia; Myelodysplastic Syndromes; LeukemiaLast Updated:July 21, 2020Completed
Condition(s):Lung Cancer; Breast Cancer; Colon Cancer; Bladder Cancer; Hepatocellular CancerLast Updated:September 10, 2022Active, not recruiting
Condition(s):Leukemia, Myeloid, AcuteLast Updated:October 17, 2023Active, not recruiting
Condition(s):Nasopharyngeal CarcinomaLast Updated:January 10, 2023Recruiting
Condition(s):Head Neck Cancer; Metastatic Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharynx Squamous Cell Carcinoma; Hypopharynx Squamous Cell Carcinoma; Larynx Squamous Cell CarcinomaLast Updated:March 6, 2024Recruiting
Condition(s):Human Papillomavirus (HPV) VaccinesLast Updated:June 26, 2023Not yet recruiting
Condition(s):Resectable Hepatocellular Carcinoma Beyond Milan CriteriaLast Updated:August 2, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.